Table 2.
Key variables identified in modelled sensitivity analysis
| Model variable | Source of variable | Level of uncertainty in data | Impact of uncertainty on model | Overall rating of importance |
|---|---|---|---|---|
| Levels of ADCrecurrence after surgery for those diagnosed through surveillance vs those presenting symptomatically | Poor published evidence plus expert opinion | High | Very high | Very important |
| Time ADC takes to become symptomatic | Poor published evidence plus expert opinion | High | Very high | Very important |
| Health state utility—Barrett's oesophagus | Value of health panel | Moderate | Very high | Very important |
| % of ADC diagnosed through surveillance that are treatable | Poor published evidence plus expert opinion | Moderate | High | Important |
| % of ADC diagnosed due to symptoms that are treatable | Poor published evidence plus expert opinion | Moderate | High | Important |
| Utility value—well after surgery | Value of health panel | Moderate | High | Important |
| Progression rate LGD to HGD | Poor published evidence plus expert opinion | High | Moderate | Moderately important |
| Progression rate HGD to ADC | Poor published evidence plus expert opinion | High | Moderate | Moderately important |
ADC, adenocarcinoma; HGD, high grade dysplasia; LGD, low grade dysplasia.